Piper Sandler Downgrades Collegium Pharmaceutical to Neutral, Maintains Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem downgraded Collegium Pharmaceutical (COLL) from Overweight to Neutral while maintaining the price target at $39.

May 10, 2024 | 9:25 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler's downgrade of Collegium Pharmaceutical to Neutral could lead to a short-term negative sentiment among investors, potentially impacting the stock's performance.
Analyst ratings, especially downgrades, can significantly influence investor sentiment and stock prices in the short term. Maintaining the price target suggests the fundamental value is recognized, but the downgrade implies a lack of near-term growth catalysts or increased risk, which could deter investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100